Infliximab
- PDF / 169,572 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 15 Downloads / 134 Views
1 S
Thyroid cancer, infusion reaction and lack of efficacy: 3 case reports In a retrospective study of 20 patients with Behcet’s disease conducted at Tokyo Women’s Medical University Hospital’s Institute of Gastroenterology, Japan between January 2003 and June 2018, three patients [ages and sexes not stated] were described, who developed thyroid cancer (1 patient), infusion reaction(1 patient) and lack of efficacy (1 patient) during treatment with infliximab for Behcet’s disease [route not stated]. The patients, who had Behcet’s disease received infliximab as induction therapy at a dose of 5 mg/kg body weight by drip infusion during weeks 0, 2, and 6, followed by maintenance therapy, which was 5 mg/kg drip infusion at 8 week intervals. At the initiation of infliximab therapy, all the patients also received prednisolone, concomitantly. Of the three patients, one patient developed thyroid cancer and one patient developed infusion reaction. The remaining patient also received azathioprine along with infliximab and prednisolone; however, this patient exhibited a lack of response (LOR) during treatment with infliximab for Behcet’s disease. The infliximab therapy was discontinued in all the patients [duration of treatment to reaction onsets and outcomes not stated]. Kambayashi H, et al. The efficacy of medium- To long-term anti-TNF-alpha antibody-based maintenance therapy in Behcet’s disease patients with intestinal lesions. Internal 803519937 Medicine 59: 2343-2351, No. 19, Oct 2020. Available from: URL: http://doi.org/10.2169/internalmedicine.5000-20
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
